On Nov 12, major Wall Street analysts update their ratings for $Evolent Health (EVH.US)$, with price targets ranging from $19 to $36.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $39 to $19.
UBS analyst Kevin Caliendo maintains with a buy rating, and adjusts the target price from $46 to $27.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and adjusts the target price from $63 to $36.
RBC Capital analyst Sean Dodge maintains with a buy rating, and adjusts the target price from $42 to $20.
Truist Financial analyst Jailendra Singh maintains with a buy rating, and adjusts the target price from $33 to $24.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
The third-quarter performance miss for Evolent Health, though disheartening, is not an outlier in the current risk climate, and the core business model continues to hold strong.
Evolent Health's Q3 EBITDA was notably below consensus, primarily due to a substantial rise in Oncology-related costs, both retrospectively and within the quarter. Nonetheless, Evolent reported signing new run-rate business amounting to $200M in Q3, which underscores the increasing demand for specialty care management.
Evolent Health's third-quarter outcomes were characterized as less than satisfactory, leading to a reassessment of its performance trajectory. Previously, it appeared that the company was poised to mitigate elevated expenses through contractual rate enhancements. However, the market's response indicates skepticism regarding Evolent's ability to achieve the anticipated $300M EBITDA target. Despite these sentiments, the prevailing belief among analysts is that the company's margins will stabilize as pricing adjustments materialize over time.
Here are the latest investment ratings and price targets for $Evolent Health (EVH.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月12日，多家華爾街大行更新了$Evolent Health (EVH.US)$的評級，目標價介於19美元至36美元。
巴克萊銀行分析師Stephanie Davis維持買入評級，並將目標價從39美元下調至19美元。
瑞士銀行分析師Kevin Caliendo維持買入評級，並將目標價從46美元下調至27美元。
TD Cowen分析師Charles Rhyee維持買入評級，並將目標價從63美元下調至36美元。
加皇資本市場分析師Sean Dodge維持買入評級，並將目標價從42美元下調至20美元。
儲億銀行分析師Jailendra Singh維持買入評級，並將目標價從33美元下調至24美元。
此外，綜合報道，$Evolent Health (EVH.US)$近期主要分析師觀點如下：
雖然Evolent Health第三季度的業績不佳令人沮喪，但在當前風險氛圍中並不是一個孤立現象，核心業務模式仍然保持強勢。
儘管Evolent Health的Q3 EBITDA明顯低於共識，主要是由於腫瘤學相關成本大幅上升，無論是回顧性的還是在本季度內。然而，Evolent報告稱，Q3簽署的新業務金額達到20000萬美元，凸顯了專科護理管理需求不斷增加。
Evolent Health第三季度的業績結果被認定爲不盡如人意，導致其績效軌跡重新評估。此前，該公司似乎已準備通過合同費率提高來降低高額支出。然而，市場的反應表明市場對Evolent實現預期的30000萬美元EBITDA目標的能力持懷疑態度。儘管存在這些情緒，分析師普遍認爲，隨着定價調整隨着時間的推移出現，公司的利潤率將穩定下來。
以下爲今日5位分析師對$Evolent Health (EVH.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
